Global Spinal Cord Stimulation (Scs) Devices Market Overview:
Spinal cord stimulation has become a popular and effective treatment option for refractory chronic pain that has not responded to conventional therapies. Technological advancements have been significant, and current neuromodulation devices have both been extremely advanced and efficient in producing good results for a variety of clinical situations of chronic pain, including failed back surgery syndrome, complex regional pain syndrome, ischemic and coronary artery disease. Despite its high initial price, this technique is likely to save money compared to different therapy strategies. Spinal cord stimulation remains an effective treatment option for chronic, disabling pain.
|Unit||Value (USD Million)|
|Key Companies Profiled||Johnson & Johnson (United States), Abbott (United States), Roche (United States), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Boston Scientific (United States), Medtronic (United States), Stimwave (United States) and Nevro (United States)|
|Customization Scope||Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility|
- Rising Prevalence Of Chronic Pain Among Adults
- Rising Number Of Patients Suffering From Spinal Cord Stimulation
- Availability Of Alternative Treatment Methods
- High Cost Of Spinal Cord Stimulation
- Technological Advancement In The Healthcare Industry
- Increasing Incidence Of The Failed Back Syndrome
- Availability Of Medical Reimbursements
- Lack Of Trained Professional
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Johnson & Johnson (United States), Abbott (United States), Roche (United States), Merck & Co. (United States), GlaxoSmithKline (United Kingdom), Boston Scientific (United States), Medtronic (United States), Stimwave (United States) and Nevro (United States). Additionally, following companies can also be profiled that are part of our coverage like Cirtec (United States) and Nuvectra (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Spinal Cord Stimulation (Scs) Devices market by 2027. Considering Market by , the sub-segment i.e. will boost the Spinal Cord Stimulation (Scs) Devices market.
On 10 September 2021, Boston Scientific has announced the European launch of FAST a new, fast-acting sub-perception therapy that the company says is clinically proven to demonstrate significant and sustained pain relief within minutes for its WaveWriter Alpha spinal cord stimulator (SCS) systems.
What Can be Explored with the Spinal Cord Stimulation (Scs) Devices Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Spinal Cord Stimulation (Scs) Devices Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Spinal Cord Stimulation (Scs) Devices
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Spinal Cord Stimulation (Scs) Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Spinal Cord Stimulation (Scs) Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.